ISDS Case Map
medicines
Coercion rather than negotiations among equal partners seems to explain the final adoption of TRIPS Agreement.
India and the Philippines begin talks for a Preferential Trade Agreement (PTA) to boost bilateral trade, building on AITIGA terms.
On January 14, President William Ruto and UAE President Sheikh Mohamed bin Zayed Al Nahyan signed the Kenya-United Arab Emirates Comprehensive Economic Partnership Agreement (CEPA), touted as the UAE’s first such deal with a mainland African country.
Consumers' Association of Penang express strong disappointment over Malaysia's rushed signing of a trade agreement with the European Free Trade Association (EFTA) countries, criticizing the government's failure to address concerns about the intellectual property (IP) provisions.
The undersigned Swiss NGOs are urging the Swiss government to actively engage within EFTA to drop these provisions known as TRIPS+.
Thai civil society organizations expressing serious concerns about the ongoing Free Trade Agreement (FTA) negotiations between Thailand and the European Union (EU), highlight potential negative impacts on agriculture, food security, environment, labor rights, public health, and other social issues.
Consumers' Association of Penang submitted a Memorandum on June 2025 to strongly urge the Malaysian government not to rush to endorse and/or sign the trade deal with EFTA. If a deal is to be signed, such a deal must not contain any TRIPS-plus obligation.
The proposed Malaysia-EFTA Economic Partnership Agreement (MEEPA) could negatively affect public health, farmers' rights, and food security in Malaysia. It includes "TRIPS-plus" intellectual property provisions that extend patent monopolies, limit access to affordable generic medicines, and increase drug costs.
Malaysian negotiators have accepted intellectual property protections above those required by the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights, which will adversely affect affordable and equitable access to medicines in Malaysia for generations.
India safeguards its $25B generic drug industry by excluding data exclusivity from the UK FTA, ensuring affordable drug access and faster generic launches.
